title: [Octreotide induces apoptosis of human hepatoma cells by the mechanism of facilitating the Fas/FasL gene expression therein].
abstract: OBJECTIVE
  To investigate the effects of octreotide on apoptosis of and Fas/FasL gene expression in human hepatoma cell mechanism of the suppression effect of liver cancer with e in order to offer the experimental foundation for clinic treatment.
  
  
  METHODS
  Hyman hematoma cells of the line SMMC-7721 were cultured and divided into two groups: octreotide group, co-cultured with octreotide 4,7, and 10 microg/ml respectively for 24 h, 48 h, or 72 h, and control group. TUNEL was used to detect the apoptosis of the cells. Flow cytometry was used with terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) technique to detect the apoptosis of the cells. FC was used with direct labeling of monoclonal antibody (CD95/CD178) to detect the expression of Fas and FasL, and the Fas/FasL ratio.
  
  
  RESULTS
  Octreotide increased the apoptotic rate of the cells dose- and time-dependently (all P < 0.05). Octreotide increased the Fas expression rate, FasL expression rate, and Fas/FasL ratio dose- and time-dependently (all P < 0.05).
  
  
  CONCLUSIONS
  Octreotide induces the apoptosis of human hepatoma cells, possibly by the mechanism of facilitating the Fas/FasL gene expression.
authors.affiliation: Department of General Surgery, Central Hospital of CNPC, Langfang 065000, China. maqizy@yahoo.com.cn
authors.forename: Qi
authors.initials: Q
authors.lastname: Ma
authors.forename: Ling-Quan
authors.initials: LQ
authors.lastname: Meng
authors.forename: Jing-Chang
authors.initials: JC
authors.lastname: Liu
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Hu
authors.forename: Jun
authors.initials: J
authors.lastname: Ge
authors.forename: Yu-Liang
authors.initials: YL
authors.lastname: Wan
authors.forename: Shan
authors.initials: S
authors.lastname: Jiang
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D053222:Fas Ligand Protein / Q000096:biosynthesis*; D005434:Flow Cytometry; D006801:Humans; D020287:In Situ Nick-End Labeling; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology; D015282:Octreotide / Q000494:pharmacology*; D013997:Time Factors; D019014:fas Receptor / Q000096:biosynthesis*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D053222:Fas Ligand Protein; D019014:fas Receptor; D015282:Octreotide